What happens when 11 years of high-ticket direct response marketing meets the lowest cost-per-lead industry I've ever seen.
Scaling campaigns and revenue for category-defining brands and personal brands across DTC and B2B verticals.
Taking high-ticket products and services from invisible to unstoppable. Not with theory — with systems that convert at scale.
My career started in the trenches of direct-to-consumer marketing. I was fortunate enough to work alongside and help scale the same team that took Jordan Belfort — the Wolf of Wall Street — to $10 million in annual revenue. That experience taught me something most marketers never learn: the gap between a mediocre offer and a 7-figure offer isn't the product. It's the system around it.
From there I moved into consumer brands — BarkBox, Dollar Beard Club — learning what it means to acquire customers at scale with disciplined cost-per-lead targets. Then came the personal brands: Ed Mylett, Marshall Sylver, and a roster of B2B companies where the game isn't volume, it's conversion quality on premium offers.
Across every industry, every campaign, every vertical — I was always hunting for the same thing: the highest possible quality lead at the lowest possible cost. Most high-ticket industries are brutal. The numbers rarely work until you've spent a lot to figure them out.
Then I found regenerative medicine. And everything changed.
This is the story of how a referral from my neighbor became the most compelling case study of my career — and why I now believe regenerative medicine is the single greatest untapped marketing opportunity in high-ticket sales.
"My neighbor called me and said he had a friend who needed help. Another marketing company had taken $40,000 from this clinic and had nothing to show for it. Zero revenue. The clinic owner was frustrated, skeptical, and running out of patience."
I had never marketed a stem cell clinic before. But after 11 years of diagnosing why campaigns fail and building systems that win, I knew exactly what I was looking at. The prior agency had treated it like a commodity product with commodity tactics. They didn't understand the buyer. They didn't understand the offer. And they didn't understand what makes this specific market different from every other high-ticket vertical.
I took the engagement. And I got to work.
Tore down everything the previous agency built. The messaging was wrong, the targeting was wrong, and the funnel was leaking at every stage. Started fresh with a single question: who is this patient, what do they want, and what does it take to get them to say yes to a premium regenerative medicine protocol?
$0 Revenue · Clock StartsNew campaign architecture live. Lead flow begins. The cost-per-lead numbers immediately stood out compared to every other high-ticket vertical I had worked in. The leads were coming in warm, educated, and motivated — the profile of a buyer, not a tire-kicker.
CPL Numbers Immediately FavorableThe clinic that had been at zero revenue for months crossed into 6-figure territory 45 days after we rebuilt the system. Not projected revenue. Not booked appointments. Collected revenue. The same clinic that another agency had taken $40,000 from with nothing to show.
✦ 6 Figures Collected · 45 DaysSix months in, the clinic crossed 7 figures in revenue. Not a fluke, not a one-time push — a repeatable, scalable system producing qualified, high-intent leads at a cost-per-lead that I had never seen work this efficiently in a high-ticket vertical. I knew at that point this wasn't just a good campaign. This was a category-defining opportunity.
✦ 7 Figures in 6 Months · Repeatable System ConfirmedIn 45 Days
Revenue in 6 Months
Prior Agency — Zero Return
"The previous agency took $40,000 and produced nothing. We rebuilt the entire system and hit 6 figures in 45 days. That's not just a good campaign — that's a broken industry meeting a working system."
After 11 years running campaigns across dozens of high-ticket industries, I have a very clear picture of what good CPL economics look like. Regenerative medicine breaks all the rules — in your favor.
The reason regenerative medicine works so well for marketing is simple: the buyer is in pain — literally. They've tried other things. They've been told surgery is their only option. They are actively searching for something different. That is the most valuable type of lead in marketing: someone who is already motivated, already educated, and already willing to pay a premium. You are not creating demand. You are meeting it.
Most regenerative medicine clinics are run by brilliant physicians who are not marketers. The competition is not smart marketing — it is almost none at all in most markets. That's the opportunity.
Most stem cell and regenerative medicine clinics are owned and operated by physicians whose entire focus is clinical excellence. Marketing is an afterthought. This means in most markets, the first clinic with a real marketing system wins.
The regenerative medicine market is growing at double digits annually. An aging population, growing distrust of surgery and pharmaceuticals, and increasing awareness of stem cell options is creating a tidal wave of inbound demand that most clinics are not capturing.
Treatments starting at $5,000 and running to $25,000+. Repeat treatments. Referral networks. A single converted patient can represent $10,000–$50,000 in lifetime clinic value. The math on marketing investment is unlike anything else I have seen in high-ticket.
In Nevada and Utah — the most permissive states in the country for regenerative medicine — the regulatory environment has opened a window that does not exist in other markets. The first clinic with professional marketing in these geographies owns the market.
I have run campaigns in real estate, financial services, cosmetic surgery, and executive coaching. The cost-per-lead in regenerative medicine relative to the ticket size and the intent level of the buyer is the best ratio I have ever seen in high-ticket marketing.
This is not a theory. The $0 to 7 figures in 6 months case study is a real clinic, real results, repeatable system. I know exactly what works, what does not, and how to scale a regenerative medicine clinic's revenue faster than any other approach in this market.
You built the clinical side. Let me build the revenue side. One conversation is all it takes to know if this is the right fit.
Results described represent a specific client engagement and are not guaranteed. Individual results will vary based on market, clinic type, geographic location, physician credentials, and execution. This case study is intended for licensed healthcare providers and medical marketing professionals. Past performance does not guarantee future results. BioVault provides marketing strategy, regenerative medicine product distribution, and physician compliance resources. © 2026 BioVault | Vital Balance Regenerative Wellness.